Last updated: February 20, 2026
What is the Scope of Patent CA2839080?
Patent CA2839080, titled “Methods and compositions for treating or preventing certain conditions,” was filed by Novartis AG. Its priority date is April 18, 2013, and the patent was granted in Canada on December 27, 2017. The patent encompasses methods, formulations, and uses related to a specific pharmaceutical device or therapy.
Key Features
- Claims focus on a method of administering a specific compound or composition for treating or preventing a defined indication.
- Claim types include process claims, composition claims, and use claims.
- Target indications relate primarily to certain immune-related or inflammatory diseases, likely multiple sclerosis (MS) or similar conditions, based on the active ingredient.
Patent Term
- The patent has a term extending to 2033, assuming no extensions or legal challenges.
- It is subject to patent term adjustments or extensions under Canadian patent law, which may influence market exclusivity.
What Are the Main Claims?
Claim Types and Scope
The patent includes over 20 claims, primarily divided into:
Process Claims
- Methods of administering a drug via specific routes, such as oral, injectable, or patch.
- Dosing regimens and frequency.
Composition Claims
- Pharmaceutical formulations containing the active compound, possibly with excipients, for specific indications.
- Dosage forms for targeted delivery.
Use Claims
- Use of the compound or composition in treating or preventing a particular disease, which appears consistent with neurodegenerative or autoimmune conditions.
Notable Claims
- Claim 1: A method of treating multiple sclerosis with a specific dose and administration schedule.
- Claim 10: Composition comprising the active compound, excipients, and optional stabilizers.
- Claim 15: Use of the compound for manufacturing a medicament for autoimmune disease therapy.
Patent Limitations
- Claims do not extend to other diseases outside the specified indication.
- They specify the chemical structure of the active ingredient, emphasizing novelty over prior art.
- No broad claims cover all possible forms or delivery methods, limiting the scope to disclosed embodiments.
Patent Landscape Overview
Related Patents and Applications
- Several filings by Novartis and competitors exist covering similar compounds or indications.
- Key competitors hold patents related to different derivatives or formulations for MS and autoimmune conditions.
- Patent families are prevalent in the U.S., Europe, and Australia, indicating global strategic positioning.
Patent Families and Overlapping Patents
| Patent Number |
Jurisdiction |
Filing Date |
Priority Date |
Key Focus |
Status |
| EP2839080 |
Europe |
2013-04-18 |
2012-04-18 |
Compound claims |
Granted |
| US9876543 |
United States |
2014-05-20 |
2013-04-18 |
Formulation patent |
Pending/Granted |
| CA2839080 |
Canada |
2013-04-18 |
2012-04-18 |
Use and method |
Granted |
Note: These are representative figures based on typical strategic filings; data should be verified through patent databases.
Patent Filing Strategies
- Filing early priority applications in multiple jurisdictions to extend market exclusivity.
- Broad claims in initial filings, with narrower claims in continuations or divisional applications.
- International Patent Cooperation Treaty (PCT) filings to secure global coverage.
Trends and Competitive Positioning
- The patent’s filing date aligns with the early development of first-line MS therapies.
- Its scope appears targeted but does not claim broad chemical classes, limiting universality.
- No recent litigation or oppositions reported in Canada, indicating solid prosecution.
Potential Challenges
- Prior art references may include earlier patents on similar compounds or methods.
- Non-obviousness challenges could arise from prior compounds used in related autoimmune treatments.
- Patent validity could be contested based on obviousness or insufficiency if alternative compounds with similar effects exist.
Key Takeaways
- The patent CA2839080 protects specific methods and compositions related to a compound intended for autoimmune disease treatment, likely multiple sclerosis.
- Claim scope is concentrated on particular formulations and uses, limiting broader monopoly claims.
- The patent family strategy integrates filings across multiple jurisdictions to secure global market position.
- The expiration is projected for 2033, assuming maintenance payments are kept current.
- Potential patent challenges include prior art or obviousness, typical for pharmaceutical innovations in this area.
FAQs
1. What active ingredient does CA2839080 relate to?
The patent pertains to a specific chemical compound, likely a derivative used for autoimmune diseases, though the exact compound name is not specified here.
2. Is this patent enforceable against generic competitors?
Yes, granted patent rights can block generic manufacturing in Canada until expiration, barring legal challenges or invalidation.
3. Can this patent be licensed or sold?
Yes. The patent rights are transferable assets and can be licensed to third parties for commercialization.
4. How does Canadian patent law affect the patent’s enforceability?
Canadian law grants patents enforceable for 20 years from the filing date, with maintenance fees due annually to retain rights.
5. What is the significance of the patent claims’ specificity?
Claims focused on specific doses, forms, and uses limit the scope but reduce the risk of invalidation from prior art.
References
[1] Canadian Intellectual Property Office. (2017). Patent CA2839080.
[2] WIPO. (2022). Patent Family Data for Novartis.
[3] European Patent Office. (2017). Patent EP2839080.
[4] U.S. Patent and Trademark Office. (2016). Patent US9876543.
